KSC · 207940.KS
Samsung Biologics Co.,Ltd.
₩1,449,000+₩83,000 (+6.08%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.08% below the high.
Loading market information…
KOE · 085660.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 05:25 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Chabiotech Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 71.9% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Chabiotech Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Chabiotech Co.,Ltd. is a global biotechnology firm specializing in the development of cell and gene therapies, particularly those involving stem and immune cells, with operations in South Korea and internationally. The company's comprehensive offerings include umbilical cord blood storage for treating intractable conditions, alongside various regenerative medicine solutions. It also manages storage services for immune and stem cells, provides anti-aging treatments, and delivers therapeutic solutions for debilitating illnesses. Furthermore, Chabiotech runs medical wellness initiatives encompassing fitness, spa services, and nutritional supplements. Leveraging its extensive research and development as well as clinical expertise, the company provides customized services covering product development, manufacturing, clinical trials, and commercialization. Chabiotech assists clients with optimizing IT system infrastructure and operations, and offers consulting services for the establishment, management, and growth of its proprietary Chaum model. Additionally, the company provides solutions for maternal-focused genomic testing and personalized healthcare. It is actively engaged in developing advanced immune cell therapies, such as CBT101 for recurrent glioblastoma and solid cancers, and both CBT111 and CAR-NK treatments specifically targeting solid tumors. Its stem cell pipeline features CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for addressing macular degeneration and Stargardt's disease. Beyond its core bio-pharmaceutical activities, Chabiotech also offers IVF (fertility) services, manufactures cosmetics and their raw materials, supplies medical devices, provides bioinsurance storage, and conducts various research services. Established in 2002, the company maintains its headquarters in Seoul, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩1,449,000+₩83,000 (+6.08%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.08% below the high.
₩192,200+₩2,900 (+1.53%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.76% below the high.
₩9,360-₩440 (-4.49%)
Pharmicell Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 55.74% below the high.
₩9,060-₩60 (-0.66%)
GC Corp.’s quoted price sits in the lower half of its reported 52-week range, 49.69% below the high.
₩8,150-₩200 (-2.4%)
MEDIPOST Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 71.99% below the high.
₩10,100+₩350 (+3.59%)
Gc Cell Corp.’s quoted price sits in the lower half of its reported 52-week range, 64.5% below the high.
₩13,420-₩660 (-4.69%)
Anterogen.Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
₩3,720-₩70 (-1.85%)
Vaxcell-Bio Therapeutics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 67.71% below the high.
